Contract Pharma Manufacturing News

31. Adcendo ApS Announces Clinical Collaboration And Supply Agreement With MSD To Evaluate ADCE-T02 In Combination With KEYTRUDA® (Pembrolizumab) In A Phase Ib Study In Patients With Advanced Solid Tumors 5/26/2026

    Adcendo ApS ("Adcendo"), a biotech company focused on the development of first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, today announced that it has entered into a clinical trial collaboration and supply agreement (the Agreement) with MSD (Merck & Co., Inc., Rahway, NJ, USA).

32. SK bioscience Signs Vaccine Technology Transfer Agreement With Colombia's VECOL To Advance Local Vaccine Manufacturing In Latin America 5/26/2026

    SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of Colombia's national vaccine localization initiative.

33. Genethon And Ampersand Biomedicines Announce Partnership To Design Novel AAV Vectors With Enhanced Tissue Specificity For More Effective And Better Tolerated Gene Therapies 5/21/2026

    Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, announce an exclusive collaboration to engineer a new generation of AAV capsids with superior tissue specificity.

34. Hanmi Pharmaceutical Partners With Organon To Export Combination Therapies To Southeast Asia 5/21/2026

    Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies’ partnership in Southeast Asia.

35. 4basebio Signs Clinical Supply Agreement To Support Phase II Clinical Trial 5/20/2026

    4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it has signed a Clinical Supply Agreement with a leading cancer immunotherapy innovator (“the Client”) to provide GMP-grade opDNA® starting material for its latest clinical programme.

36. Modernizing mRNA Quality Control 5/20/2026

    Oxford Nanopore Technologies, a company delivering a new generation of nanopore-based molecular sensing technology, and Lonza today announced the launch of a new technology approach designed to modernize and accelerate GMP quality control testing for mRNA therapeutics.

37. Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement For U.S. Commercialization Rights To IMPAVIDO® (Miltefosine) 5/19/2026

    Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) from an affiliate of Knight Therapeutics, Inc (“Knight”).

38. Hansa Biopharma Enters Into €115M Licensing Agreement With SERB Pharmaceuticals For IDEFIRIX In Europe And MENA 5/19/2026

    Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

39. FAMAR Group Announces Contract Manufacturing Agreement With GE HealthCare 5/19/2026

    FAMAR Group, a leading European pharmaceutical Contract Development and Manufacturing Organization (CDMO), has signed a contract manufacturing agreement with GE HealthCare to fill and finish vials of GE HealthCare's iodine-based contrast media, at its newly acquired site in Homburg, Germany, with commercial supply due to begin in 2028.

40. LOTTE Biologics Expands Antibody Manufacturing Agreement With Ottimo Pharma 5/18/2026

    LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership.